Article
Oncology
Trang H. Nguyen Vu, Osamu Kikuchi, Shinya Ohashi, Tomoki Saito, Tomomi Ida, Yukie Nakai, Yang Cao, Yoshihiro Yamamoto, Yuki Kondo, Yosuke Mitani, Shigeki Kataoka, Tomohiro Kondo, Chikatoshi Katada, Atsushi Yamada, Junichi Matsubara, Manabu Muto
Summary: This study proposes a novel therapeutic strategy combining trifluridine/tipiracil and MK1775 as a treatment for esophageal squamous cell carcinoma. Trifluridine induces DNA damage in cancer cells, and the WEE1 inhibitor enhances this effect. The combination treatment significantly suppresses tumor growth.
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Oncology
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro
Summary: This study aims to compare the efficacy and safety of trifluridine/tipiracil plus ramucirumab with trifluridine/tipiracil monotherapy as third- or later-line treatments for advanced gastric cancer and esophagogastric junction adenocarcinoma.
Review
Oncology
John K. Waters, Scott Reznik
Summary: This review provides a summary of the epidemiology, diagnosis, staging, and treatment of esophageal squamous cell carcinoma (ESCC). Recent findings suggest that novel approaches to screening can be cost-effective in high-incidence regions. Multi-disciplinary evaluation and treatment, including endoscopic resection and minimally invasive esophagectomy, have become the standard of care. Additionally, immunotherapy has shown promising results in improving survival for patients with metastatic or persistent disease.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Oncology
Yi-Min Gu, Qi-Xin Shang, Yue Zhuo, Jian-Feng Zhou, Bo-Wei Liu, Wen-Ping Wang, Guo-Wei Che, Long-Qi Chen
Summary: Immune checkpoint inhibitors as second- or later-line therapy may improve overall response rate and overall survival for patients with locally advanced or metastatic esophageal squamous cell carcinoma. Patients treated with immune checkpoint inhibitors might experience fewer treatment-related adverse events, especially grade >= 3, compared with those treated with chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Rui-Yan Zhang, Shi-Jie Zhu, Peng Xue, Sheng-Qi He
Summary: This case report describes an 82-year-old male patient diagnosed with esophageal squamous cell carcinoma, who developed cutaneous metastasis. Despite receiving chemotherapy and other treatments, the patient's condition worsened and eventually resulted in multiple organ failure.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Immunology
Junfeng Zhao, Shaoyu Hao, Jing Tian, Ying Li, Dan Han
Summary: This study compares the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) combined with radical esophagectomy. The results show that NCRT has a significantly better pathologic response and prognosis than NICT in the treatment of patients with locally advanced ESCC. However, the safety profiles of NCRT and NICT are similar.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Review
Immunology
Mengjie Jiang, Yujie Hu, Gang Lin, Chao Chen, Huafeng Li
Summary: This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, outlines the clinical trials that merit attention, and discusses unresolved issues and future research directions in this field. The findings suggest that radio-immunotherapy combination may improve treatment outcomes, highlighting the importance of patient selection and the need for further research to optimize treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Xiao Ma, Weixin Zhao, Bin Li, Yongfu Yu, Yuan Ma, Mathew Thomas, Yawei Zhang, Jiaqing Xiang, Yiliang Zhang
Summary: Neoadjuvant immune checkpoint inhibitors (ICI) plus chemotherapy are safe and effective in locally advanced esophageal squamous cell carcinoma (ESCC) patients who refuse or do not have access to radiotherapy, improving surgical feasibility, downstaging tumors, relieving dysphagia symptoms, and extending survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Shou-Wu Lee, Sheng-Shun Yang, Han-Chung Lien, Yen-Chun Peng, Chun-Fang Tung, Teng-Yu Lee
Summary: The study aimed to evaluate the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) as first-line therapy for advanced-stage hepatocellular carcinoma (HCC) patients. The results showed that this combination treatment provides acceptable antitumor efficacy, and there were no differences in survival outcomes between different drug combinations.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Linlin Xiao, Chi Lin, Yueping Liu, Yajing Wu, Jun Wang
Summary: This article reports a rare case of an ESCC patient whose brain metastatic lesion completely disappeared after receiving ICIs treatment, providing supporting data for the use of ICIs as an option for treating brain metastases in ESCC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Yuntae Kim, Shun Yamamoto, Ken Kato
Summary: Esophageal cancer is a common malignancy, with esophageal squamous cell carcinoma being the predominant subtype. Effective treatment options for patients with this subtype are limited. The use of immunotherapy, specifically nivolumab, has shown promising results in the treatment of metastatic esophageal cancer. This review discusses the efficacy and safety of postoperative nivolumab and explores the potential use of immune checkpoint inhibitors in the perioperative therapy of locally advanced esophageal squamous cell carcinoma.
CANCER MANAGEMENT AND RESEARCH
(2023)
Review
Gastroenterology & Hepatology
Yong Liu
Summary: This review provides an overview of perioperative immunotherapy for resectable ESCC, focusing on the role of immune checkpoint inhibitors during the perioperative period. The review also explores promising biomarkers and offers insights into future prospects.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Toshiharu Hirose, Shun Yamamoto, Ken Kato
Summary: Nivolumab has been approved for treatment after prior chemotherapy in patients with advanced ESCC and has shown survival benefits in patients with resectable EC. Ongoing trials evaluating nivolumab-containing treatments may improve the clinical outcomes for patients with advanced and locally advanced EC.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Oncology
Irene Tsung, Francis P. Worden, Robert J. Fontana
Summary: This study reviewed the experience of using immune checkpoint inhibitors (ICIs) in solid organ transplant (SOT) recipients with advanced head and neck cutaneous squamous cell carcinoma (cSCC). The data suggest that minimizing calcineurin inhibitors and converting to mTOR inhibitors along with prophylactic steroids may allow for the safe use of ICIs in this population. Short-term efficacy appears promising, but further prospective studies and standardized protocols for prophylactic steroids are necessary.
Article
Gastroenterology & Hepatology
Ayaka Mizumoto, Shinya Ohashi, Mayumi Kamada, Tomoki Saito, Yukie Nakai, Kiichiro Baba, Kenshiro Hirohashi, Yosuke Mitani, Osamu Kikuchi, Junichi Matsubara, Atsushi Yamada, Tsukasa Takahashi, Hyunjin Lee, Yasushi Okuno, Masashi Kanai, Manabu Muto
JOURNAL OF GASTROENTEROLOGY
(2019)
Article
Oncology
Kenshiro Hirohashi, Shinya Ohashi, Yusuke Amanuma, Yukie Nakai, Tomomi Ida, Kiichiro Baba, Yosuke Mitani, Ayaka Mizumoto, Yoshihiro Yamamoto, Osamu Kikuchi, Junichi Matsubara, Atsushi Yamada, Shin'ichi Miyamoto, Hiroshi Seno, Tomonari Matsuda, Manabu Muto
Article
Genetics & Heredity
Nilay S. Sethi, Osamu Kikuchi, Gina N. Duronio, Matthew D. Stachler, James M. McFarland, Ruben Ferrer-Luna, Yanxi Zhang, Chunyang Bao, Roderick Bronson, Deepa Patil, Francisco Sanchez-Vega, Jie-Bin Liu, Ewa Sicinska, Jean-Bernard Lazaro, Keith L. Ligon, Rameen Beroukhim, Adam J. Bass
Article
Oncology
Yosuke Mitani, Masashi Kanai, Tadayuki Kou, Shigeki Kataoka, Keitaro Doi, Junichi Matsubara, Shinya Ohashi, Shigemi Matsumoto, Manabu Muto
Article
Gastroenterology & Hepatology
Masashi Tamaoki, Akira Yokoyama, Takahiro Horimatsu, Kenshiro Hirohashi, Yusuke Amanuma, Hirokazu Higuchi, Yosuke Mitani, Masahiro Yoshioka, Shinya Ohashi, Manabu Muto
Summary: Repeated tPDT could be an effective and safe treatment option for esophageal cancer patients with local failure even after salvage tPDT.
Article
Multidisciplinary Sciences
Yosuke Mitani, Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Ayaka Mizumoto, Yoshihiro Yamamoto, Tomoki Saito, Shigeki Kataoka, Junichi Matsubara, Atsushi Yamada, Masashi Kanai, Shigemi Matsumoto, Hiroaki Sakai, Kiyotsugu Yoshikawa, Eijiro Nakamura, Manabu Muto
Summary: Clinical cancer genome sequencing can detect potential targets for cancer treatment and variants of unknown significance. This study found that a HER2 mutation in colorectal cancer has oncogenic potential when accompanied by loss of APC function. The findings suggest that this HER2 mutation may be a potential therapeutic target for colorectal cancer.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Tomoyuki Abe, Yoshihito Horisawa, Osamu Kikuchi, Hitomi Ozawa-Umeta, Atsuhiro Kishimoto, Yasuhiro Katsuura, Atsushi Imaizumi, Tadashi Hashimoto, Kotaro Shirakawa, Akifumi Takaori-Kondo, Kosuke Yusa, Tadashi Asakura, Hideaki Kakeya, Masashi Kanai
Summary: Curcumin 13-D-glucuronide sodium salt (TBP1901), a prodrug form of aglycone curcumin, has been found to have significant antitumor effects in vivo. The conversion of TBP1901 into aglycone curcumin is dependent on the enzyme glucuronidase (GUSB). Additionally, aglycone curcumin inhibits NF-kappa B signaling pathways and induces the production of reactive oxygen species (ROS) to exert its antitumor effects.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Tianxia Li, Osamu Kikuchi, Jin Zhou, Yichen Wang, Babita Pokharel, Klavdija Bastl, Prafulla Gokhale, Aine Knott, Yanxi Zhang, John G. Doench, Zandra V. Ho, Daniel V. T. Catenacci, Adam J. Bass
Summary: Gastroesophageal adenocarcinomas (GEAs) frequently exhibit amplification of KRAS gene, resulting in overexpression of WT KRAS protein. This study investigates potential targets to enhance the efficacy of SHP2 inhibition in KRAS-amplified GEA, including those within the MAPK pathway and upstream RTKs. In vitro and in vivo experiments demonstrate that pan-ERBB kinase inhibition has potent cytotoxicity. Additionally, the combination of CDK4/6 inhibition with SHP2 inhibition shows greater efficacy in KRAS-amplified GEA compared to KRAS-mutant tumors. These findings suggest potential therapeutic combinations for clinical study in KRAS-amplified GEAs.
Article
Oncology
Trang H. Nguyen Vu, Osamu Kikuchi, Shinya Ohashi, Tomoki Saito, Tomomi Ida, Yukie Nakai, Yang Cao, Yoshihiro Yamamoto, Yuki Kondo, Yosuke Mitani, Shigeki Kataoka, Tomohiro Kondo, Chikatoshi Katada, Atsushi Yamada, Junichi Matsubara, Manabu Muto
Summary: This study proposes a novel therapeutic strategy combining trifluridine/tipiracil and MK1775 as a treatment for esophageal squamous cell carcinoma. Trifluridine induces DNA damage in cancer cells, and the WEE1 inhibitor enhances this effect. The combination treatment significantly suppresses tumor growth.
Correction
Cell Biology
Norihide Jo, Yu Hidaka, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Masahiko Aoki, Masaki Yamamoto, Miki Nagao, Satoshi Morita, Takako E. E. Nakajima, Manabu Muto, Yoko Hamazaki
Article
Cell Biology
Norihide Jo, Yu Hidaka, Osamu Kikuchi, Masaru Fukahori, Takeshi Sawada, Masahiko Aoki, Masaki Yamamoto, Miki Nagao, Satoshi Morita, Takako E. Nakajima, Manabu Muto, Yoko Hamazaki
Summary: Impaired CD4(+) T cell responses in older adults result in weaker humoral and cellular immunity and reduced systemic reactogenicity after mRNA COVID-19 vaccination. Older adults show fewer spike-specific CD4(+) T cells, including CXCR3(+) circulating follicular helper T cells and T(H)1 helper T cells, after the first dose, correlated with lower IgG levels and fewer adverse effects after the second dose compared to younger adults. Inefficient CD4(+) T cell response after the first dose may lead to decreased production of helper T cytokines, resulting in lower immune response and reduced reactogenicity.
Article
Oncology
Kiichiro Baba, Motoo Nomura, Shinya Ohashi, Takuya Hiratsuka, Yukie Nakai, Tomoki Saito, Yuki Kondo, Keita Fukuyama, Osamu Kikuchi, Atsushi Yamada, Junichi Matsubara, Kenshiro Hirohashi, Yosuke Mitani, Ayaka Mizumoto, Manabu Muto
AMERICAN JOURNAL OF CANCER RESEARCH
(2020)